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Abstract
Pancreatic cancer, the fourth leading cause of cancer
death in the United States, is frequently associated with
the amplification and deletion of specific oncogenes
and tumor-suppressor genes (TSGs), respectively. To
identify such novel alterations and to discover the
underlying genes, we performed comparative genomic
hybridization on a set of 22 human pancreatic cancer
cell lines, using cDNA microarrays measuring f26,000
human genes (thereby providing an average mapping
resolution of <60 kb). To define the subset of amplified
and deleted genes with correspondingly altered expres-
sion, we also profiled mRNA levels in parallel using
the same cDNA microarray platform. In total, we iden-
tified 14 high-level amplifications (38–4934 kb in size)
and 15 homozygous deletions (46–725 kb). We dis-
covered novel localized amplicons, suggesting pre-
viously unrecognized candidate oncogenes at 6p21,
7q21 (SMURF1, TRRAP ), 11q22 (BIRC2, BIRC3), 12p12,
14q24 (TGFB3), 17q12, and 19q13. Likewise, we identi-
fied novel polymerase chain reaction–validated homo-
zygous deletions indicating new candidate TSGs at
6q25, 8p23, 8p22 (TUSC3), 9q33 (TNC, TNFSF15), 10q22,
10q24 (CHUK ), 11p15 (DKK3 ), 16q23, 18q23, 21q22
(PRDM15, ANKRD3), and Xp11. Our findings suggest
candidate genes and pathways, which may contribute
to the development or progression of pancreatic cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States. With a 5-year survival rate of less
than 5%, mortality rates closely mirror incidence rates, re-
flecting the ineffectiveness of current treatment regimens [1].
An improved understanding of the molecular pathogenesis
of pancreatic cancer is urgently needed to identify new
targets and strategies for effective therapy [2].
As with other solid tumor types, the amplification of onco-
genes and deletion of tumor-suppressor genes (TSGs) play a
critical role in the development and progression of pancreatic
cancer. Activating mutations—and less frequently amplifica-
tion [3,4]—of the KRAS2 oncogene (12p12), for example, have
been identified as early events in nearly all pancreatic adeno-
carcinomas [2]. Likewise, the CDKN2A, TP53, and SMAD4
TSGs are frequently deleted or inactivated by mutation or
promoter hypermethylation [2]. Indeed, the discovery of homo-
zygous deletions first led to the identification of CDKN2A and
SMAD4 as important TSGs [5,6].
Pancreatic cancers likely harbor additional localized DNA am-
plifications and deletions that are not apparent by conventional
cytogenetic techniques such as comparative genomic hybridiza-
tion (CGH) [7]. Array-based CGH (aCGH) methods provide an
alternative higher-resolution approach for identifying these
lesions [8–10]. In the current study, we have performed a cDNA
microarray-based CGH analysis to identify localized DNA ampli-
fications and deletions in a set of pancreatic cancer cell lines. In
parallel, we have measured mRNA levels using the same micro-
array platform, thereby defining the subset of amplified/deleted
genes displaying correspondingly altered expressions.
Materials and Methods
Pancreatic Cancer Cell Lines
AsPC-1, BxPC-3, Capan-1, Capan-2, CFPAC-1, HPAC,
HPAF-II, Hs 766T, MIA PaCa-2, MPanc96, PANC-1, Panc
Abbreviations: aCGH, array-based comparative genomic hybridization; FISH, fluorescence in
situ hybridization; TSG, tumor-suppressor gene
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02.03, Panc 02.13, Panc 03.27, Panc 08.13, Panc 10.05,
PL45, SU.86.86, and SW 1990 were obtained from the
American Type Culture Collection (ATCC, Manassas, VA).
PL5 and PL8 were obtained from Dr. Anirban Maitra (Johns
Hopkins University, Baltimore, MD). Colo-357 was a kind gift
of Dr. Caroline Hill (Cancer Research UK London Research
Institute, London, UK). Cell lines (Table W1) were grown to
80% confluence in RPMI 1640 medium supplemented with
10% fetal bovine serum. Genomic DNA was isolated using
the Qiagen (Valencia, CA) Blood and Cell Culture DNA
Maxi Kit, and RNA was isolated using the Trizol (Invitrogen,
Carlsbad, CA) method.
Array CGH and Gene Expression Profiling
cDNA microarrays spotted on Corning (Corning, NY)
UltraGAPS coated slides were obtained from the Stanford
Functional Genomics Facility (Stanford, CA). These arrays
contain 39,632 human cDNA, representing approximately
25,856 mapped human genes (22,890 UniGene clusters
[11] together with 2966 additional mapped expressed se-
quence tags not assigned UniGene IDs). aCGH and gene
expression profiling were performed essentially as described
[12,13]. Briefly, for aCGH, 4 mg of genomic DNA from each
cell line was random primer– labeled with Cy5 and cohybri-
dized to the cDNA microarray along with 4 mg of Cy3-labeled
sex-matched normal leukocyte reference DNA. For gene
expression profiling, 50 mg of total RNA from each cell line
and 50 mg of reference RNA (derived from 11 different estab-
lished human cell lines) were differentially labeled with Cy5 and
Cy3, respectively, and cohybridized to cDNA microarrays.
Following overnight hybridization and washing, arrays were
imaged using a GenePix 4000B scanner (Axon, Union City,
CA). Fluorescence ratios were extracted using GenePix Pro
5.0 software, and the data were uploaded into the Stanford
Microarray Database [14] for storage, retrieval, and analysis.
The complete microarray datasets are available at http://
smd.stanford.edu.
Data Analysis
For aCGH, background-subtracted fluorescence ratios
were normalized for each array by setting the average fluo-
rescence ratio for all array elements equal to 1. Genes were
considered reliably measured if the fluorescence intensity
for the Cy3 reference channel was at least 1.4-fold above
background. Map positions for arrayed cDNA clones were
assigned using the NCBI genome assembly, accessed
through the UCSC genome browser (July 2003 freeze). For
genes represented by multiple arrayed cDNA, the aver-
age fluorescence ratio was used. DNA copy number gains
and losses were identified using the CLuster Along Chro-
mosomes (CLAC) method (http://www-stat.stanford.edu/
fwp57/CGH-Miner) [15]. Briefly, the CLAC algorithm builds
a hierarchical cluster–style tree along each chromosome,
such that neighboring genes with positive and negative ratios
are separated into different clusters. Gains and losses are
then called significant based on the height and width of clus-
ters, and a false discovery rate is estimated by comparison to
normal–normal hybridization data. We defined high-level DNA
amplifications and presumptive homozygous deletions as
contiguous regions identified by CLAC, with at least 50% of
genes displaying fluorescence ratios z3 or V0.25, respec-
tively. For expression profiling, fluorescence ratios were nor-
malized for each array, and then well-measured genes
(fluorescence intensities for the Cy5 or Cy3 channel at
least 1.5-fold above background) were subsequently ‘‘mean-
centered’’ (i.e., reported for each gene relative to the mean
ratio across all samples).
Fluorescence In Situ Hybridization (FISH)
To validate DNA amplification, we performed interphase
FISH using a SpectrumGreen–labeled bacterial artificial chro-
mosome probe corresponding to the 7q21 locus (RP11-62N3;
Children’s Hospital Oakland Research Institute, Oakland, CA)
and a Spectrum Orange–labeled chromosome 7 centromere
probe (CEP 7; Vysis, Downers Grove, IL). FISH was per-
formed exactly according to the Vysis labeling and hybridiza-
tion protocols, and images were captured using an Olympus
(Melville, NY) BX51 microscope and CytoVision 3.0 software
(Applied Imaging Corp., San Jose, CA).
Polymerase Chain Reaction (PCR) Validation
of Homozygous Deletions
To validate homozygous deletions, we used gene-specific
primer pairs to PCR-amplify genomic DNA from cell lines.
Primer pairs for genes flanking the regions of homozygous de-
letion, and designed to have a distinguishable fragment size,
were included in the PCR reactions as internal controls. PCR
was performed on an Applied Biosystems (Foster City, CA)
GeneAmp 9700, using 100 ng of DNA template, 1 PCR
buffer (Applied Biosystems), 160 mM dNTPs, 1.5 mM MgCl,
10 pmol of each individual primer (Table W2), and 1 U of
TaqDNApolymerase (AppliedBiosystems) in a25-ml reaction
for 35 cycles [94jC, 30 seconds; annealing temperature
(Table W2), 30 seconds; 72jC, 30 seconds], followed by gel
electrophoresis on a 1.8% TAE agarose gel, and visualization
using an Alpha Innotech (San Leandro, CA) imaging system.
Results
To identify DNA amplifications and deletions, we performed
CGH on a set of 22 pancreatic adenocarcinoma cell lines
using cDNA microarrays measuring 25,856 human genes,
thereby providing an average mapping resolution of less
than 60 kb. We identified numerous chromosomal regions
of recurrent gain and loss (Figures W1 and W2), the spec-
trum of which was consistent with published conventional
CGH studies [4,16–20]. Gains were most commonly ob-
served on chromosomes 8q (90%), 11q (75%), 20q (75%),
7q (65%), 3q (60%), 5q (60%), and 7p (60%), whereas
losses occurred most often on 18q (95%), 8p (80%), 4q
(70%), 6q (65%), 9p (65%), 17p (65%), 3p (60%), 6p (60%),
and Xp (60%). Cell lines PL45 and Panc 10.05 displayed
highly similar aCGH profiles, consistent with their being
established from the same patient. Surprisingly, cell lines
AsPC-1 and MPanc96, the latter obtained both from the
ATCC repository and from the originator [21], also exhibited
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nearly identical profiles. Given that AsPC-1 was established
15 years earlier [22], we conclude that both cell lines likely
represent AsPC-1.
In addition to these broad regions of chromosomal gain and
loss, we also identified numerous localized high-level DNA
amplifications (i.e., fluorescence ratios z3, corresponding to
at least five-fold amplification [9]; Table 1) and presump-
tive homozygous deletions (i.e., fluorescence ratios V0.25;
Table 2). All together, we identified 14 high-level amplifications
in eight different cell lines, each spanning 38–4934 kb in size
(median 747 kb), and 15 homozygous deletions in 13 cell lines,
spanning 46–725 kb (median 183 kb).
Several localized high-level amplifications corresponded
to known oncogenes, including KRAS2 (12p12) [3,23] and
AKT2 (19q13) [24]; each of these genes was amplified in two
pancreatic cancer cell lines. In addition, we identified several
novel high-level amplifications, suggesting the location of as
yet uncharacterized oncogenes. Nonrecurrent amplified loci
Table 1. High-Level DNA Amplifications Identified by aCGH.
Cytoband P Border (nt) Q Border (nt) Size (kb) Cell Line Remaining Lines with
Low-Level Gain
Selected Candidate
Oncogenes*
6p21 32,043,837 32,410,885 367 SW 1990 4/19 STK19, TNXB,
PBX2, NOTCH4
6p21 32,827,514 32,865,810 38 SW 1990 0/19 TAP1
7q21 93,671,907 98,605,497 4934 AsPC-1 9/19 TRRAP, SMURF1,
ARPC1A, ARPC1B
11q13 69,241,850 70,008,988 767 Colo-357 14/19 CCND1, EMS1
11q22 101,406,590 102,133,375 727 Colo-357 4/19 YAP1, BIRC2, BIRC3,
MMP7, MMP27
12p12 14,926,093 15,186,368 260 Su.86.86 4/19
12p12 25,253,402 26,380,345 1127 Su.86.86 5/19 KRAS2
12p11 25,253,402 27,366,920 2114 HPAF-II 5/19 KRAS2, FGHR1OP2,
STK38L
14q24 74,414,776 74,540,126 125 Panc 08.13 6/19 TGFB3
17q12 36,065,530 36,106,569 41 CFPAC-1 5/19
19q13 39,957,195 40,808,091 851 Su.86.86 8/19 USF2
19q13 43,616,179 45,546,133 1930 PANC-1 7/19 eIF3k, AKT2
19q13 43,997,907 46,073,560 2076 Su.86.86 7/19 AKT2
19q13 55,171,535 55,539,817 368 Su.86.86 6/19 ZNF473
*Boldface type indicates that gene expression was well measured by microarray analysis and elevated when amplified.
Table 2. Homozygous Deletions Identified by aCGH.
Cytoband P Border Q Border (nt) Size (kb) Cell Lines(s) Remaining Lines with
Single-Copy Loss
Gene Deletions Confirmed
by PCR
6q25 157,305,093 157,562,885 258 MIA PaCa-2 0/19 ARID1B
8p23 1,717,413 1,894,213 177 MIA PaCa-2 13/19 CLN8, ARHGEF10
8p22 15,108,999 15,639,496 530 MIA PaCa-2 14/19 TUSC3
9p21*,y 21,845,793 21,984,872 139 BxPC-3, Capan-1,
MIA PaCa-2,
PANC-1, Panc
02.13, PL5,
Su.86.86
6/13 CDKN2A
9q33 (a*) 112,922,979 113,392,575 470 BxPC-3 6/19 TNFSF15z, TNFSF8,
TNC, DEC1z
10q22* 72,655,409 72,861,236 206 BxPC-3 4/19 CDH23z
10q24 101,574,438 101,620,286 46 PL8 4/19 CHUK
11p15 11,942,981 12,118,344 175 BxPC-3 4/19 DKK3
16q23 78,558,946 78,688,790 130 HPAF-II 4/19 WWOX
18q21y 46,766,091 46,863,399 97 BxPC-3, CFPAC-1,
Hs 766T, Panc
03.27, PL8
14/15 SMAD4
18q21* 49,277,732 50,003,145 725 MIA PaCa-2 18/19 DCC, MBD2
18q23 75,921,728 76,104,374 183 Colo-357 13/19 PARD6G
21q22 41,433,815 41,822,285 388 Panc 02.13 6/19 BACE2, MXI1, ANKRD3,
PRDM15
21q22 41,822,119 42,524,687 703 BxPC-3 6/19 ANKRD3, PRDM15,
ZNF295z
Xp11 42,636,923 42,787,663 151 BxPC-3, MIA
PaCa-2
6/18 MAOA
*Just over 0.25 ratio cutoff, but homozygous deletion was confirmed by PCR.
yBoundaries vary between cell lines; approximate site of common deletion is indicated.
zCandidate TSG within deletion, but not represented on microarray.
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included 6p21, 7q21, 11q22, 12p12 (proximal to KRAS2),
14q24, 17q12 (proximal to ERBB2), and 19q13 (proximal
and distal to AKT2) (Table 1). Of the genes residing within
these amplicons, several displayed correspondingly ele-
vated expression and have plausible roles in tumorigenesis.
Among these, the 7q21 amplicon ‘‘peak’’ [25] in AsPC-1
(Figure 1A) harbors SMURF1, an E3 ubiquitin ligase and
negative regulator of TGFb signaling [26]. Also residing in
this amplicon are ARPC1A and ARPC1B, subunits of the
ARP2/3 complex that controls actin polymerization and cell
motility [27], and TRRAP, an essential cofactor for the tran-
scriptional oncoproteins Myc and E2F [28]. We independently
validated the 7q21 amplicon by interphase FISH (Figure 1C).
Within the 11q22 amplicon in Colo-357 (Figure 1B), the
apoptotic inhibitors BIRC2 and BIRC3 [29] were highly ex-
pressed. TGFB3, a ligand for TGFb signaling [30], was found
amplified at 14q24 in Panc 08.13.
Wealso identified numerous localized, presumptive homo-
zygous deletions. Several such alterations corresponded to
known TSGs, including CDKN2A (9p21), homozygously de-
leted in seven cell lines, and SMAD4 (18q21), homozygously
deleted in five cell lines (Table 2). Interestingly, the MIA
PaCa-2 cell line harbors a homozygous deletion in the DCC
gene, adjacent to but not affecting SMAD4, supporting a po-
tential tumor-suppressor function for this gene [31]. In addi-
tion, we discovered several novel PCR-validated, localized
homozygous deletions, suggesting new candidate TSGs at
6q25, 8p23, 8p22, 9q33, 10q22, 10q24, 11p15, 16q23,
18q23, 21q22, and Xp11 (Table 2). Among these, the 8p22
deletion in MIA PaCa-2 harbors TUSC3, a poorly character-
ized gene also homozygously deleted in ametastatic prostate
cancer [32]. TNC, which modulates cell adhesion [33], and
TNFSF15, a vascular endothelial inhibitor [34], reside within
the 9q33 deletion in BxPC-3. The 10q23 deletion in PL8
harbors CHUK (also called IKKA), an activator of NF-nB sig-
naling [35]. DKK3 [36], an inhibitor of Wnt signaling [37], re-
sides within the 11p15 deletion in BxPC-3 (Figure 2, A and
C ); an additional four cell lines displayed single-copy loss at
Figure 1. Array CGH identifies localized DNA amplifications in pancreatic cancer. (A and B) Graphic displays of DNA copy number alteration for selected localized
amplifications identified in pancreatic cancer cell lines. Test/reference fluorescence ratios are plotted on a log2 scale according to chromosome nucleotide
(Megabase) position. Shaded regions highlight localized high-level amplifications. Insets display genes within highlighted amplicons, ordered by map position and
color-coded according to mean-centered expression levels (log2 ratio scale indicated). (A) 7q21 amplicon in AsPC-1. (B) 11q22 amplicon in Colo-357. Complete
genomewide profiles of DNA copy number alteration for the 22 pancreatic cancer cell lines are viewable in Figure W2. (C) FISH validation of 7q21 amplification in
AsPC-1. Spectrum Orange chromosome 7 centromere probe detects three signals, whereas Spectrum Green 7q21 locus probe identifies multiple signal clusters
indicative of DNA amplification. Nonamplified cell line BxPC-3 (triploid for chromosome 7) is shown for comparison.
Array CGH Analysis of Pancreatic Cancer Bashyam et al. 559
Neoplasia . Vol. 7, No. 6, 2005
this site. The 21q22 locus (Figure 2, B and D), homozygously
deleted in BxPC-3 and Panc 2.13 (with an additional six lines
displaying single-copy loss), includes PRDM15, a putative
histone methyltransferase, a class of enzymes frequently de-
regulated in human cancer [38], and ANKRD3 (also called
RIP4), another activator of NF-nB signaling [39].
Discussion
The main objective of our study was to use aCGH to identify
localized DNA amplifications and deletions in pancreatic
cancer, thereby defining the location of previously unrecog-
nized candidate oncogenes and TSGs. In our aCGH analysis
of 22 pancreatic adenocarcinoma cell lines, we identified
14 localized high-level amplifications and 15 localized homo-
zygous deletions. Few of these localized aberrations had
been identified earlier by conventional chromosome-based
CGH [17,18]. Our findings therefore highlight the usefulness
of high-resolution aCGH in discovering previously unrecog-
nized DNA copy number aberrations. Notably, compared to
broad chromosomal gains and losses, such highly localized
aberrations also provide better opportunities to pinpoint and
discover the underlying cancer genes.
As noted, the spectrum of gains and losses we observed
was consistent with previous conventional CGH studies on
primary pancreatic tumors. Furthermore, the observed sub-
set of localized aberrations harboring known cancer genes
(i.e., KRAS2, AKT2, CDKN2A, and SMAD4) has been well
described in primary pancreatic tumors, suggesting that
most novel aberrations are likely also to be found in primary
tumor specimens. Nevertheless, as cells may acquire gene-
tic changes during establishment and passage of cultures,
the prevalence of these novel aberrations in primary pancre-
atic tumors will need to be determined.
Although our findings are, in general, consistent with
previous chromosome-based CGH studies of the same
Figure 2. Array CGH identifies localized homozygous DNA deletions in pancreatic cancer. (A and B) Test/reference fluorescence ratios are plotted on a log2 scale
according to chromosome nucleotide (Megabase) position. Shaded regions highlight localized homozygous deletions. Insets display genes within highlighted
deletions, ordered by map position and color-coded according to mean-centered expression levels (log2 ratio scale provided; unfilled green bar indicates measured
intensity less than background). (A) 11p15 deletion in BxPC-3. (B) 21q22 deletion in BxPC-3 and Panc 02.13. (C) PCR validation of homozygous deletion at 11p15.
DKK3, located within the homozygous deletion, is PCR-amplified in control cell line Panc 02.13 but not in BxPC-3. TEAD1, a control gene flanking the deletion, is
PCR-amplified in both cell lines. (D) PCR validation of homozygous deletion at 21q22. PRDM15, located within the homozygous deletion, is PCR-amplified in
control cell lines (MiaPaCa2 and PL8) but not in BxPC-3 and Panc 02.13. HMGN1, a control gene flanking the deletion, is PCR-amplified in all four cell lines.
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pancreatic cell lines, we did not identify the frequent gain of
1q reported by Tirado et al. [40], which may represent an
artifact of the chromosome-based CGH method [41]. Three
aCGH studies of pancreatic cell lines were also recently
published. Holzmann et al. [42] surveyed 13 cell lines (five
in common with our study) using BAC arrays with low-
resolution coverage (498 clones), providing limited data for
comparison. Aguirre et al. [43] profiled 24 cell lines (18 in
common) using cDNA arrays (14,160 clones); however,
their focus on broad low-level gains/losses, along with
their not reporting which alterations were identified in
which cell lines, makes meaningful comparisons difficult.
Heidenblad et al. [44] studied 31 cell lines (nine in com-
mon) using BAC (3565 clones) and cDNA (25,468 clones)
arrays, and their data were reported in sufficient detail to
permit comparisons. Although our findings are in general
agreement for the common set of cell lines investigated,
we have identified several additional aberrations and can-
didate genes (Table W3), including the PCR-verified homo-
zygous deletions at 11q and 21q (Figure 2). Discrepancies
likely reflect the higher mapping resolution of our arrays
and/or the different thresholds for calling gains and losses.
Our findings suggest several new candidate genes and
pathways in pancreatic cancer. For example,SMURF1 (7q21),
amplified and overexpressed in AsPC-1, encodes an E3
ubiquitin ligase, which targets the degradation of TbRI recep-
tor complex through its association with Smad7, thus sup-
pressing the growth-inhibitory effects of TGFb [26] (more
frequently accomplished through SMAD4 disruption). In
contrast, our discovery of TGFB3 (14q24) amplification in
Panc 08.13 supports a possible tumorigenic role of Smad4-
independent TGFb signaling in pancreatic cancer [45]. Other
alterations highlight the importance of inhibiting apoptosis,
through amplification and overexpression of the antiapop-
totic genes BIRC2 and BIRC3 (11q22), or possible modula-
tion of NF-nB signaling [46] by deletion of CHUK (10q24) or
ANKRD3 (21q22). Interestingly, we identified DKK3 (11p15),
an inhibitor of Wnt signaling, within a highly localized homo-
zygous deletion in the BxPC-3 cell line. Other cell lines
exhibited single-copy loss and/or decreased expression of
DKK3, suggesting that aberrant Wnt signaling may be com-
mon in pancreatic cancer. Although altered Wnt signaling
contributes to the development of human cancers, most
notably colorectal cancer [47], few reports to date have im-
plicated Wnt signaling in the pathogenesis of pancreatic
adenocarcinoma. However, consonant with our findings,
Caca et al. [48] identified constitutive Tcf (the downstream
effector of canonical Wnt signaling) transcriptional activity in
two pancreatic cell lines.
In conclusion, our high-resolution genomewide aCGH
study has led to the identification of numerous previously
unrecognized localized DNA amplifications and deletions in
pancreatic cancer. The expression levels, along with the
known or inferred functions of the genes residing within these
aberrations, suggest several new candidate oncogenes and
TSGs. Our findings provide insight into the pathogenesis of
pancreatic cancer, and may suggest new targets for improved
therapies. Additional studies are required to characterize the
functional role of identified genes in the development or
progression of pancreatic cancer.
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Table W1. Pancreatic Cancer Cell Lines.
Cell Line Gender Origin Source Reference
AsPC-1 Female Nude mouse xenograft of ascites
cells from patient with pancreatic
adenocarcinoma
ATCC Chen, W.H. et al. (1982).
In Vitro, 18, 24–34.
BxPC-3 Female Pancreatic adenocarcinoma ATCC Tan, M.H. et al. (1986).
Cancer Invest, 4, 15–23.
Capan-1 Male Liver metastasis of pancreatic
adenocarcinoma
ATCC Fogh, J. et al. (1977).
J Natl Cancer Inst, 58, 209–14.
Capan-2 Male Pancreatic adenocarcinoma ATCC Kyriazis, A.A. et al. (1986). Cancer Res,
46, 5810–5.
CFPAC-1 Male Liver metastasis of pancreatic
ductal adenocarcinoma
ATCC Schoumacher, R.A. et al. (1990).
Proc Natl Acad Sci U S A, 87, 4012–6.
Colo-357 Female Lymph node metastasis of
pancreatic adenocarcinoma
Dr. Caroline Hill,
London Research Institute
Morgan, R.T. et al. (1980). Int J Cancer,
25, 591–8.
HPAC Female Nude mouse xenograft of a
moderate to well differentiated
pancreatic adenocarcinoma of
ductal origin
ATCC Gower, Jr., W.R. et al. (1994).
In Vitro Cell. Dev. Biol. 30A: 151–161
HPAF-II Male Peritoneal ascites from pancreatic
adenocarcinoma with mets to liver,
diaphragm and lymph nodes
ATCC Kim, Y.W. et al. (1989). Pancreas, 4, 353–62.
Hs 766T Male Lymph node metastasis of
pancreatic cancer
ATCC Owens, R.B. et al. (1976). J Natl Cancer Inst,
56, 843–9.
MIA PaCa-2 Male Primary pancreatic carcinoma ATCC Yunis, A.A., et al. (1977). Int J Cancer,
19, 218–35.
MPanc96 Male Primary malignant pancreatic
adenocarcinoma
ATCC Peiper, M. et al. (1997). Int J Cancer,
71, 993–9
PANC-1 Female Primary pancreatic adenocarcinoma
from pancreatic duct
ATCC Lieber, M. et al. (1975). Int J Cancer,
15, 741–7.
Panc 02.03 Female Primary pancreatic adenocarcinoma
from head of pancreas
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
Panc 02.13 Female Primary pancreatic adenocarcinoma
from head of pancreas
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
Panc 03.27 Female Primary pancreatic adenocarcinoma
from head of pancreas
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
Panc 08.13 Male Primary pancreatic adenocarcinoma
from head of pancreas
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
Panc 10.05 Male Primary pancreatic adenocarcinoma
from head of pancreas
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
PL45 Male Poorly differentiated primary
pancreatic adenocarcinoma of
ductal origin
ATCC Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
PL5 Male Primary pancreatic adenocarcinoma Dr. Anirban Maitra,
Johns Hopkins University
Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
PL8 Male Primary pancreatic adenocarcinoma Dr. Anirban Maitra,
Johns Hopkins University
Jaffee, E.M. et al. (1998). Cancer J Sci Am,
4, 194–203.
SU.86.86 Female Liver metastasis of a pancreatic
ductal carcinoma
ATCC Drucker, B.J. et al. (1988).
In Vitro Cell Dev Biol, 24, 1179–87.
SW 1990 Male Spleen metastasis of a grade II
pancreatic adenocarcinoma
ATCC Kyriazis, A.A. et al. (1986). Cancer Res,
46, 5810–5.
Array CGH Analysis of Pancreatic Cancer Bashyam et al.
Neoplasia . Vol. 7, No. 6, 2005
Table W2. PCR Primer Sequences for Validation of Homozygous Deletion.
Cytoband Gene Cell Line(S) Forward Primer Reverse Primer SIZE (bp)
6q25 ARID1B MIA PaCa-2 TCCGAACATATCCAGTATTCCA CAACGGTCAGACTCTGCGTA 111
8p23 CLN8 MIA PaCa-2 ACACTGTTCCGAGAGTTCCATA CTGATGATGAGTCCCAAGGT 278
8p23 ARHGEF10 MIA PaCa-2 ACTTTATTGATGAAGTCAGACAGCA CTTAGCCAAATATGTTCTAGGTTGC 102
8p22 TUSC3 MIA PaCa-2 GATTGAGGATTTGATGGAAAGC TCCTCTGGGAATCCAGACTT 129
9p21 CDKN2A BxPC-3, Capan-1, MIA PaCa-2,
PANC-1, Panc 02.13, PL5, Su.86.86
TTTATTCATTTGCTTGTGGCC GGTCCCGATTTAGAAGGAGC 120
9q33 TNFSF15 BxPC-3 CTCTGCACTGGGAACATGAA TTGGCTCAGGGTAGCTGTCT 228
9q33 TNFSF8 BxPC-3 TATTTCATAGAGGAGACCTAGGAGG CAAATCAGCAGTGGTGGTATG 125
9q33 TNC BxPC-3 GCCTCACCTCCTCTGTGATT AAAAAGGGATGGCTTCCAAT 271
9q33 DEC1 BxPC-3 ATAAGTAATCACAAGGTACAGGGAA CTTTTGGAGAACCATATGTTAAATC 135
10q22 CDH23 BxPC-3 TGGGAATTCTCAACAGGTCC ACGGGGAGCATCTACCAAG 161
10q24 CHUK PL8 TTCTCTGAAACCCTTGGGG TGCTGCTTGATGATGAGAGG 145
11p15 DKK3 BxPC-3 CTTTAAACTTTAAGAACTCTGG ACTTAGGTAATTGTAGGGC 231
16q23 WWOX HPAF-II TGAGGGCAGGATACCACTTC CAGAGACTGAGATGGCCACA 394
18q21 SMAD4 BxPC-3, CFPAC-1, Hs 766T,
Panc 03.27, PL8
TCCTTCCCCAGATGACCATAGT GGCAGGGTGTGGTGTGTAAAGGG 164
18q21 DCC MIA PaCa-2 GGCCCACTCTTCCTAAGACC TTACACAGCGCCAGTCAATC 202
18q21 MBD2 MIA PaCa-2 GAATGAGGTGGATGGTAAATCA TGTGACTTGTTTGTCTGCTTCA 131
18q23 PARD6G Colo-357 GAGGGACGCAGATGAGAAAA CAGGGCACATTTAGGAAGGA 135
21q22 BACE2 Panc 02.13 GAACCCCGCACTCCTACATA TGCTCTGGTGCATTTTGAAG 119
21q22 MX1 BxPC-3, Panc 02.13 GCAAGGTGGAGCGATTC GTTAGCCGTGGTGATTTAGC 158
21q22 ANKRD3 BxPC-3, Panc 02.13 TGGAAAAGTATCCTGCCCAC TCACCTGTGTCCCATAGGGT 164
21q22 PRDM15 BxPC-3, Panc 02.13 ACGGGTCACAGCACCTTT ATGCTCTAGCGTGTGACGTG 291
21q22 ZNF295 BxPC-3 AGCCGGAGACTTCGCATAGT AGTTTGAGTGTCTGCGGGAG 277
Xp11 MAOA BxPC-3 TTAAATGGTCTCGGGAAGG GCCCAATGACACAGCCTTT 488
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Table W2. (continued )
Flanking Gene Forward Primer Reverse Primer Size (bp) Annealing Temp
SYNJ2 TTGCAGCTTTCCTTCCCAAT GACCCCAAGCCTAGTCCCTT 243 57
MYOM2 TATACCCGTCTAAGGGAGAAAGC GTGTGTTGTCTGCCAACCC 111 56
CSMD1 TGATGCCGAGGTCACTG CCTCTTGGAGTATTAAAGTGGAAC 141 58
CTSB GGAGCCCTTTGGAGAAC TGAGCCGCGTCATTAG 201 55
ACO1 AATGTGTTCTCCCAAACCG CAGAGTGAATCATCCAGACTCC 167 56
CIP98 TGGATGAATTCTCGAGTGACC CCCAGGACAAGTGGGTTGG 167 56
CIP98 TGGATGAATTCTCGAGTGACC CCCAGGACAAGTGGGTTGG 167 58
CIP98 TGGATGAATTCTCGAGTGACC CCCAGGACAAGTGGGTTGG 167 55
CIP98 TGGATGAATTCTCGAGTGACC CCCAGGACAAGTGGGTTGG 167 56
PCDB AGCTGAGGAGCCCTTACC TATTGTTGCTGGGAAGTTGC 210 56
PAX2 GACCGCCACTAGTTACCGC GCTCCACCCGTCCTGTCC 205 57
TEAD1 GATAAGGGGTGAAGTTTTCT TGCTTGGTAGAAGTGTCC 122 53
MAF AAGCACATAGGAACAACACGC TTTCAGGGACTGACATCCTG 166 59
MALT1 ACCTTCTGCAACTTCATCCAGTA GTAACCACCATTCTGCTGGG 249 59
MALT1 ACCTTCTGCAACTTCATCCAGTA GTAACCACCATTCTGCTGGG 249 58
MALT1 ACCTTCTGCAACTTCATCCAGTA GTAACCACCATTCTGCTGGG 249 57
NFATC1 ACTGTGTGATGTCCCGTTAGTGA TATTCCTAAAGGTGCCTGCAAAA 290 58
HMGN1 CTGAGATTTTATTGGTTGAGGATCA AACTGGTGGGCCGTATGTAA 216 57
HMGN1 CTGAGATTTTATTGGTTGAGGATCA AACTGGTGGGCCGTATGTAA 216 58
HMGN1 CTGAGATTTTATTGGTTGAGGATCA AACTGGTGGGCCGTATGTAA 216 57
HMGN1 CTGAGATTTTATTGGTTGAGGATCA AACTGGTGGGCCGTATGTAA 216 57
HMGN1 CTGAGATTTTATTGGTTGAGGATCA AACTGGTGGGCCGTATGTAA 216 58
CHST7 ATGATTACAAAAACGCCAGACA AATAGCTCCGTCTCCCTTTACC 132 56
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Table W3. Comparison to Aberrations identified by Heidenblad et al. [44].
Cytoband P-Border (nt) Q-Border (nt) Size (Kb) Cell Line Selected Candidate Genes
Amplifications
6p21* 32,043,837 32,410,885 367 SW 1990 STK19, TNXB, PBX2, NOTCH4
6p21* 32,827,514 32,865,810 38 SW 1990 TAP1
7q21* 93,671,907 98,605,497 4,934 AsPC-1 TRRAP, SMURF1, ARPC1A, ARPC1B
11q13§ 69,241,850 70,008,988 767 Colo-357 CCND1, EMS1
11q22§ 101,406,590 102,133,375 727 Colo-357 YAP1, BIRC2, BIRC3, MMP7, MMP27
12p12y 14,926,093 15,186,368 260 Su.86.86
12p12y 25,253,402 26,380,345 1,127 Su.86.86 KRAS2
12p11z 25,253,402 27,366,920 2,114 HPAF-II KRAS2, FGHR1OP2, STK38L
14q24§ 74,414,776 74,540,126 125 Panc 08.13 TGFB3
17q12z 36,065,530 36,106,569 41 CFPAC-1
19q13y 39,957,195 40,808,091 851 Su.86.86 USF2
19q13* 43,616,179 45,546,133 1,930 PANC-1 eIF3k, AKT2
19q13y 43,997,907 46,073,560 2,076 Su.86.86 AKT2
19q13* 55,171,535 55,539,817 368 Su.86.86 ZNF473
Deletions
6q25§ 157,305,093 157,562,885 258 MIA PaCa-2
8p23§ 1,717,413 1,894,213 177 MIA PaCa-2 ARID1B
8p22§ 15,108,999 15,639,496 530 MIA PaCa-2 CLN8, ARHGEF10
9p21* 21,845,793 21,984,872 139 BxPC-3, Capan-1, MIA PaCa-2, PANC-1,
Panc 02.13, PL5, Su.86.86
TUSC3
9q33* 112,922,979 113,392,575 470 BxPC-3 CDKN2A
10q22* 72,655,409 72,861,236 206 BxPC-3 TNFSF15, TNFSF8, TNC, DEC1
10q24§ 101,574,438 101,620,286 46 PL8 CDH23
11p15z 11,942,981 12,118,344 175 BxPC-3 CHUK
16q23z 78,558,946 78,688,790 130 HPAF-II DKK3
18q21* 46,766,091 46,863,399 97 BxPC-3, CFPAC-1, Hs 766T,
Panc 03.27, PL8
WWOX
18q21z 49,277,732 50,003,145 725 MIA PaCa-2 SMAD4
18q23§ 75,921,728 76,104,374 183 Colo-357 DCC, MBD2
21q22§ 41,433,815 41,822,285 388 Panc 02.13 PARD6G
21q22z 41,822,119 42,524,687 703 BxPC-3 BACE2, MXI1, ANKRD3, PRDM15
Xp11z 42,636,923 42,787,663 151 BxPC-3, MIA PaCa-2 ANKRD3, PRDM15, ZNF295
MAOA
*Aberration also identified by Heidenblad et al.
yAberration identified by Heidenblad et al., but not resolved into two distinct amplicons as here.
zAberration not identified by Heidenblad et al.
§Cell line not studied by Heidenblad et al.
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Figure W1. Consensus plot of DNA copy number alterations identified with the CLuster Along Chromosomes (CLAC) method (15) using the CGH-Miner software
(http://www-stat.stanford.edu/~wp57/CGH-Miner). Frequencies of gain and loss are plotted for each gene locus using a colorimetric and height scale (indicated).
Cell lines Panc 10.05 and MPanc-96 are excluded from this frequency plot, so as to not over-represent duplicated samples (see main text).
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Figure W2. Genome-wide aCGH profiles of DNA copy number alteration for the 22 pancreatic cancer cell lines. A normal male-female DNA control hybridization is
also provided. Fluorescence ratios are plotted on a log10 scale, here as a moving average of 5 adjacent genes, according to chromosome position where red and
green indicate positive and negative ratios, respectively. Centromeres are indicated by black bar.
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